ライフサイエンスコーパス: active group

1 improvement in the balance step test in the active group).

2 ess increased significantly over time in the active group.

3 s designed as a whole, not only on the redox-active group.

4 and remission rates were also higher in the active group.

5 cial potential drop experienced by the redox-active group.

6 d intraocular pressure trended higher in the active group.

7 increase in IgE+ cells in patients from the active group.

8 percentage of responders were greater in the active group.

9 nt increase of mites-specific IgG4 levels in active group.

10 uctivity and a higher concentration of redox-active groups.

11 was no significant difference between the 2 active groups.

12 ue to adverse effects was more common in the active groups.

13 systemic reactogenicity were similar across active groups.

14 a, and ability to predictably organize redox-active groups.

15 nt decrease in FeNO level comparable in both active groups.

16 n a flavin cofactor and a disulfide as redox-active groups.

17 y weight and activity groups, with the least-active group (15.7 +/- 9.9 min MVPA/d, 6062 +/- 1778 ste

18 body weight (86.3 +/- 13.2 kg) and the most-active group (174.5 +/- 60.5 min MVPA/d, 10260 +/- 3087

19 Thus, (+)-9 is the first orally active group 2 mGluR agonist described thus far and is a

20 ation due to adverse events was 4% (7 in the active group, 2 in the placebo group).

21 ely depressed (mean EPDS score 21.8 [SD 3.0] active group, 21.3 [2.9] placebo group; SADS scores, 66.

22 in the number of circulating bacteria in the active group (3.5 x 10(4) vs. 3.1 x 10(3) colony-forming

23 GMT, and FI-GMT, respectively) vs. the least active group ( 30 min/week).

24 after enrollment of 100 participants (50 in active group, 50 in sham group) when a promising zone th

25 isorders the most commonly observed class in active groups (52 [61%] for 2.5 mg, 64 [75%] for 5.0 mg,

26 -HRQL score was significantly greater in the active group (56%) compared with the sham group (18.5%;

27 on neuropsychological measures (47.7% in the active group; 63.1% in younger participants).

28 M) performance significantly improved in the active group after GVC (p=0.008), and remained stable in

29 ion scores were significantly reduced in the active group after six months.

30 nitroxide radicals are incorporated as redox-active groups along polypeptide backbones to function as

31 estimates for secondary outcomes favored the active group, although the differences were not statisti

32 rimary endpoint was -0.028 (SD 0.453) in the active group and -0.108 (0.528) in the control group; es

33 r the start of treatment were -212.5 for the active group and -97.8 for the placebo group (P = .0040)

34 tor score decreased by 17.3 +/- 17.6% in the active group and 11.8 +/- 15.8% in the placebo group (le

35 sitized, and 284 were randomized (146 to the active group and 138 to the placebo group).

36 31 patients in the active group and 29 in the control group completed the s

37 Remission rates were 29.2% in the active group and 29.0% in the sham group (P = 0.95).

38 nts occurred in 34 (22%) participants in the active group and 30 (19%) in control group (p=0.487), no

39 Response rates were 41.7% in the active group and 36.4% in the sham group (P = 0.6).

40 sis, 121 (76%) were randomly assigned to the active group and 39 (24%) to the control group.

41 xperienced a confirmed CVD event (406 in the active group and 390 in the placebo group).

42 Forty-nine patients in the active group and 53 in the sham group underwent 12 weeks

43 For protein, it was 57% +/- 3 in the active group and 60% +/- 3 in the sham group (difference

44 ed by the enteral route was 64% +/- 2 in the active group and 65% +/- 2 in sham patients for calories

45 Of these, 18 events were reported in the active group and 8 in the control group.

46 For vitamin C, there were 97 cases in the active group and 96 in the placebo group (HR, 0.99; 95%

47 orted symptoms significantly declined in the active group and did not decline in the control group.

48 Seventeen of 27 patients in active group and none of 13 patients in control group (P

49 (24 of 39 participants; 95% CI 45-78) in the active group and none of the control group after the fir

50 penultimate phosphodiester bond by providing active groups and coordination bonds to the RNAP active

51 erence in hrHPV clearance between the pooled active groups and placebo (20/64 (31.3%) vs 10/30 (33.3%

52 trated a global treatment effect between the active groups and placebo, hence confirming the study dr

53 in IgE, IgG, and IgG4 responses between both active groups and the placebo group but no consistent di

54 Differences in OXPHOS diminished between active groups and UT when normalising to mitochondrial v

55 ssions of tDCS delivered at 2 mA for 20 min (active group) and 1 min (sham group) while participants

56 8 times as high for individuals in the least-active group as for those in the middle activity group.

57 Relative dropout rates in placebo and active groups as well as reasons for dropout were also a

58 tiator and which presents the polymerization active group at the growing polymer chain end.

59 VRE infections in the VRE-active vs non-VRE-active groups at 7 [0 (0.0 %) vs 2 (3.2 %), p=0.222], 14

60 r 20-mers), of the d or l configuration with active groups at the N or C termini, were bound at 5-32

61 sIgG4 raised only in active group (Bet v 1: P = 0.054, Gly m 4: P = 0.037), a

62 ssessment showed a tendency in favour of the active group but did not reach statistical significance.

63 There was more vomiting in the active group but no other important differences were det

64 oc analysis found nine (43%) patients in the active group but no placebo patients with a large clinic

65 ary hypothesis tested for superiority of the active groups combined vs expectant management, and a se

66 mission rate was significantly higher in the active group compared to that in the sham group with a r

67 power at the frontal region increased in the active group compared to the sham group.

68 mmetry (towards the right hemisphere) in the active group compared to the sham group.

69 without disability among the most physically active group compared with sedentary adults (adjusted od

70 ty: improved odds of being event-free in the active group compared with the control group.

71 a inducible protein-10 (IP-10) expression in active groups compared to inactive groups.

72 th an additional stepwise improvement in the active groups compared to placebo, which was significant

73 IgG1 increased significantly in all active groups compared to placebo.

74 symptom score significantly decreased in all active groups compared with placebo (-18.8% for placebo

75 A similar safety profile was found for both active groups compared with the placebo group.

76 For 24 weeks after treatment, the active group continued unsupervised home exercise while

77 m group and 9.68 (95% CI, 8.11-11.25) in the active group, corresponding to 31.87% and 54.7% score re

78 ial sorption of NOM components rich in redox-active groups (e.g., quinone, polyphenols) and (ii) surf

79 The caries-active group exhibited significantly lower degrees of sa

80 These nucleophilic fragments serve as redox active groups for performing subsequent transformations.

81 cluded all operated patients: eight from the active group, four from the sham group who were submitte

82 ter bond released a fraction of the Fc redox active groups from the electrode surface, decreasing the

83 and the burial depth of the voltammetrically active groups from the surface concentration dependence

84 Among participants with plaque, the most active group (>2000 MET-min/wk) had a lower prevalence o

85 Compared with the sham, the active group had a significantly higher remission rate a

86 Ten percent (15/154) of infants in the active group had AD compared with 19% (27/145, P = .030)

87 At 54 months, 2 additional patients in the active group had become responders.

88 meworks (COFs) containing well-defined redox-active groups have become competitive materials for next

89 %) in the placebo group, and 96 (36%) in the active group (hazard ratio 1.11, 95% CI 0.83-1.49; p=0.4

90 ncy hospital attendance was 45% lower in the active group (hazard ratio, 0.55; 95% confidence interva

91 found between the stable moderate and always active groups (hazard ratio = 1.24, 95% confidence inter

92 The most active group, however, had a more benign composition of

93 ngstrom crystal structure of a catalytically active group I intron splicing intermediate containing t

94 nts in the RNA and yielded the catalytically active group I intron structure.

95 stitutions grossly disrupt the catalytically-active group I intron tertiary structure, and that CYT-1

96 The constitutively active Group I mGluR-Homer1a complex is involved in the

97 This demonstrates that only one redox-active group (i.e., the covalent FAD cofactor) is involv

98 l, hydrodynamic and structural properties of active group II intron RNP particles (+A) isolated from

99 drug that delivers to the brain BCI-632, the active Group II mGluR antagonist metabolite.

100 alues were significantly lower in the caries-active group in comparison with the caries-free and cari

101 espectively, show that FAD is the only redox-active group in nikD.

102 lysing oxidation and reduction of chemically active groups in surface-anchored N-heterocyclic carbene

103 eted with essential contributions from other active groups in the field.

104 owever, sRaw was significantly better in the active group (kiloPascal/second, geometric mean [95% CI]

105 tion within 30 days was not lower in the VRE-active group (log-rank p=0.16 at Kaplan-Meier analysis;

106 ; 95% CI, 1.28-9.97) compared with the least active group (<1000 MET-min/wk).

107 GMT, and FI-GMT, respectively) vs. the least active group (<=30 min/week).

108 MADRS scores were significantly lower in the active group (mean [SD], 30.4 [4.8] at baseline; 10.5 [6

109 e first 8-week intervention was 0.89 for the active group (n = 113) and -0.06 for the placebo group (

110 The active group (n = 131) received 250 mg (weight 18-35.9 k

111 18.5% (95% CI, 12.5%-24.1%; P < .001) in the active group (n = 150) over that observed in the placebo

112 Patients in the active group (n = 36) received CLS-TA and aflibercept at

113 The active group (n = 87) received 250 mg (weight <40 kg) or

114 pants screened were randomly assigned to the active group (n=153) or control group (n=158).

115 ary individuals to one of two groups: (i) an active group of 102 individuals walking downwards a pred

116 ubiquitous macromolecule that serves as the active group of proteins involved in many cellular proce

117 Incident AF was more frequent in the active groups of both trials, reaching statistical signi

118 yl group on SAM via amide bond and unreacted active groups of LC-SPDP were blocked using 1% ethanol a

119 we show that partial mobility restriction of active groups of the drug molecule suggests why this car

120 ipid peroxidation by direct interaction with active groups of these lipids and could also contribute

121 teractions arising from densely packed redox-active groups, only when prepared as thin films.

122 d using independent t-test, and DeltaG among active groups (or inactive groups) were compared using A

123 ma exacerbation to receive mite-impermeable (active group) or control (placebo group) bed encasings.

124 her active therapeutic stimulation settings (active group) or subtherapeutic stimulation settings (co

125 the control group compared with an effective active group over time, ultimately reducing the statisti

126 percentage of CD4(+)CD25(+) was lower in the active group (P < .05) and correlated with changes in CD

127 e ratings than in low-calorie ratings in the active group (P = 0.001).

128 9 ng/mL in the controls vs. 2.1 ng/mL in the active group (p =.05).

129 f CRTh2 was observed between the placebo and active groups (P = 0.047).

130 men was 20% to 35% higher than in the 2 less active groups (P:<0.01).

131 t one measure (41.3% of declines occurred in active group participants; 63.0% in older participants r

132 Additionally, a subset of the active group participated in semi-structured interviews

133 sity; no Pa was detected on Day 28 in 8 of 8 active group patients compared with 1 of 13 placebo grou

134 of the polymer chains are terminated by the active groups (Ph-C(=S)-S-) derived from RAFT agents, an

135 density than the RA and UT groups while all active groups (RA, RUN and XC) displayed higher mass-spe

136 ed uptake throughout the putamen only in the active group, ranging from 25% (left anterior putamen; P

137 Women in the physically active group (ratio of TEE to RMR = 1.89 +/- 0.08) gaine

138 n that study, participants randomized to the active group received a total of 4-weeks of active iTBS,

139 The active group received aerosolized FP once daily for 5 da

140 Compared with the control group, eyes in the active group received fewer treatments (scheduled plus a

141 groups were included: the placebo group and active groups receiving 0.2 or 0.37 mug of Alt a 1 per d

142 Nineteen of 46 patients (41%) in the active group reported 26 mild adverse effects and 7 of 4

143 n a nearly dose-response manner in the least active groups reporting <150 MVPA min/week.

144 icipate and were divided into two groups: an active group (SEELOT) and a waiting-list group (WLC).

145 itizations to mites, while 3 patients in the active group showed neosensitization to shrimp with nega

146 of eczema decreased in both groups, but the active group showed significantly greater improvements i

147 Both active groups showed significant improvement in quality

148 ct to the other two subtypes), with the TP53-active group showing better prognosis.

149 In the high Mr enzyme, a third redox active group shuttles the reducing equivalent from the a

150 ficant symptom reduction was observed in the active group (t = -4.404, d = -0.704, p < 0.001) but not

151 months, significantly fewer children in the active group than in the placebo group had attended the

152 ance with exacerbations was 27% lower in the active group than in the placebo group, but this did not

153 len exposure was in all seasons lower in the active group than in the placebo group, with relative di

154 ot statistically significantly higher in the active group than in the sham group (-1.96 [0.12] vs -1.

155 ke value ratio at 6 months was higher in the active group than in the sham group (0.78 [95% CI, 0.77-

156 PPI therapy was higher among patients in the active group than in the sham group by intention-to-trea

157 ted, but scalp pain was more frequent in the active group than the sham group (17.4% vs 4.4%).

158 and oxygen delivery tended to be greater in active groups than in controls.

159 or photosensitivity were more common in the active groups than with placebo.

160 This creates a new surface with more "active" groups that can form new hydroxyl bridges.

161 For the active group, the baseline mean (SD) visual analog scale

162 g defects act synergistically with the polar active groups to enhance the enzymatic electrostatics.

163 rscores the potential of incorporating redox-active groups to expand the scope of FLP chemistry, pavi

164 ks, frequently show a progression from tiny, active groups to huge, stable communities, which is insu

165 ing moieties or chemical modifications using active groups to integrate different contrast properties

166 84% (95% CI 70-93) of the active group tolerated daily ingestion of 800 mg protein

167 ilter, which is positively charged with DEAE active groups, traps low-molecular-weight DNA fragments.

168 e induction are dependent on a catalytically active Group V sPLA(2).

169 change of -9.0 (IQR: -13 to -5) days in the active group versus +3.0 (IQR: -1.0 to + 5.0) days in th

170 lter monitoring in 36 out of 70 (51%) in the active group versus 22 out of 76 (29%) in the sham group

171 pH < 4 was significantly improved within the active group versus baseline (7 vs 10, 18%, P < .001) bu

172 cal (20% vs 21%) morbidity were found in the active group versus the placebo group.

173 d IgG(4) levels, were demonstrated for the 2 active groups versus the placebo group.

174 by a median (IQR) 100% (46% to 100%) in the active group vs increased by 325% (112% to 412%) in sham

175 Fewer filters were deemed permanent in the active group vs passive group (5 of 313 [1.6%] vs 47 of

176 the observed data (full analysis set) in the active groups vs the placebo group were 0.09 (95% CI, 0.

177 ive, with non-significant worsening for both active groups vs. placebo in the P50 and minimal between

178 ne mean (SD) physical function score for the active group was 32.3 (9.2) and the week-13 score was 27

179 DeltaG in the active groups was 33.7-59.0 higher than that in the inac

180 In the active group, we observed increased levels of GABA in vm

181 In the active group, we provided multifaceted educational inter

182 d ratios (HRs) for poor renal outcome in the active group were 0.68 (95% CI, 0.44-1.04), 1.09 (0.86-1

183 ecies found to be overabundant in the caries-active group were Actinomyces sp. strain B19SC, Streptoc

184 The most common adverse events in the active group were headache (17%), fatigue (16%), and nau

185 Children in the active group were significantly more frequently sensitiz

186 Statistical differences between placebo and active groups were all significant above 500 mTU, being

187 bo group was discontinued and thereafter the active groups were continued, and participants initially

188 transcription systems contain electrophilic active groups, whereas lycopene and nonxanthophylic caro

189 ill also receive EGb 761 and patients in the active group will extend their treatment duration.

190 agent that combines two complementary chemo-active groups within a single molecular architecture, we